Therapeutic treatment of chronic myelogenous leukemia by adminis

Details Therapeutic treatment of chronic myelogenous leukemia by adminis Therapeutic treatment of chronic myelogenous leukemia by adminis

1994-02-25

1995-03-28

Rollins, John W.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536 2763, 536 277, A61K 3170

Patent

active

054017246

ABSTRACT:
A process for the treatment of chronic myelogenous leukemia in mammals is disclosed that utilizes a 2-halo-2'-deoxyadenosine derivative as the active treating agent.

REFERENCES:
patent: 4751221 (1988-06-01), Watanabe et al.
patent: 4918179 (1990-04-01), Watanabe et al.
patent: 5034518 (1991-07-01), Montgomery et al.
patent: 5106837 (1992-04-01), Carson et al.
patent: 5310732 (1994-05-01), Carson
Carson et al.(I), "Antileukemic and Immunosuppressive Activity of 2-Chloro-2'-deoxyadenosine," Proc. Nat. Acad. Sci. USA, 81, 2232-2236 (1984).
Platanias et al., "Hairy Cell Leukaemia: The Role of Alpha Interferon," Eur. J. Cancer, 27(Supp. 4), S53-S57 (1991).
Petzer et al., "Inhibitory Effect of 2-Chlorodeoxyadenosine on Granulocytic, Erythroid, and T-Lymphocytic Colony Growth," Blood, 78(10), 2583-2587 (1991).
Jehn et al., "New Drugs in the Treatment of Acute and Chronic Leukemia with Some Emphasis on m-AMSA," Anticancer Research, 11, 705-712 (1991).
Carson et al.(II), "Programmed Cell Death and Adenine Deoxynucleotide Metabolism in Human Lymphocytes," Adv. Enzyme Regul., 27, 395-404 (1988); MEDLINE, Abstr. No. 89269905; Only Abstract provided.
Scholtz, "New Drugs and Other Treatments in the Management of Cancer," Am. J. Pharm., 164, 15-22 (1992).
Textbook of Medicine, Cecil. 18th Ed., Wyngaarden et al. eds., W. B. Saunders Co., 1992, Philadelphia, Pa., pp. 933-949.
Reiter et al., "A Dual Anti-Tumor Effect of a Combination of Interferon-.alpha. and 5-Fluorouracil or 2-Chlorodeoxyadenosine on Natural Killer (NK) Cell Mediated Cytotoxicity," in Purine and Pyrimidine Metabolism in Man, Part A, Harkness et al. eds., Plenum Press, New York, 1991, pp. 69-73.
Ho, "Chemotherapy of Chronic Haematological Malignancies," Balliere's Clin. Haematology, 4(1), 197-221 (1991).
Piro et al., "2-Chlorodeoxyadenosine: An Effective New Agent for the Treatment of Chronic Lymphocytic Leukemia," Blood, 72(3), 1069-1073 (1988).
Beutler et al., "2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside," Leukemia and Lymphoma, 5, 1-8 (1991).
Gandhi et al., "Cell Cycle-Specific Metabolism of Arabinosyl Nucleosides in K562 Human Leukemia Cells," Cancer Chemother. Pharmacol., 31, 11-17 (1992).
Klein, IMMUNOLOGY The Science of Self-Nonself Discrimination, John Wiley & Sons, New York, 1982, pp. 92-94 and 98-101.
Saven et al., "Complete Hematologic Remissions in Chronic-Phase, Philadelphia Chromosome-Positive, Chronic Myelogenous Leukemia after 2-Chlorodeoxyadenosine," Cancer, 73(12), 2953-2963 (1994).

Affiliated with

Also associated with

Rating

Therapeutic treatment of chronic myelogenous leukemia by adminis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic treatment of chronic myelogenous leukemia by adminis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic treatment of chronic myelogenous leukemia by adminis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2250596